Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang(Sun Yat-sen University), Xiaoli Wei(Sun Yat-sen University), Fenggong Wang(Sun Yat-sen University), Nong Xu(Zhejiang University), Lin Shen(Peking University), Guanghai Dai(Chinese PLA General Hospital), Xianglin Yuan(Tongji Hospital), Y. Chen(Sichuan University), S. Yang(Zhengzhou University), Jiawei Shi, Xiang Hu(Shanghai Medical College of Fudan University), Xiandong Lin(Fujian Medical University), Qilong Zhang(Harbin Medical University), J. Feng(Jiangsu Cancer Hospital), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Yanshi Liu(First Hospital of China Medical University), W. Li(Jilin University), Yongqian Shu(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Yi Jiang(Shantou University), Quan Li(Shanghai Jiao Tong University), J.W. Wang(Sun Yat-sen University), H. T. Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu(Sun Yat-sen University)
Cited by 475Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis